huCART19-IL18(University of Pennsylvania)(huCART19-IL18(University of Pennsylvania))

概要

基本信息

药物类型

自体CAR-T

别名-

靶点

CD19 x IL18R1

作用机制

CD19抑制剂(B淋巴细胞抗原CD19抑制剂)、IL18R1激动剂(白细胞介素18受体激动剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构

University of Pennsylvania

在研机构

University of Pennsylvania

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

2

项与 huCART19-IL18(University of Pennsylvania) 相关的临床试验

NCT04684563 / Recruiting临床1期IIT

Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to find the maximum dose of huCART19-IL18 cells that is safe for use in humans with CD19+ cancers.

开始日期2021-05-06

申办/合作机构

University of Pennsylvania

NCT03620058 / Active, not recruiting临床1期IIT

Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) Alone and When Co-administered With Humanized Anti-CD19 Chimeric Antigen Receptor Redirected T Cells (huCART19) In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

This is a single center, open-label, phase 1 study to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.

开始日期2018-09-27

申办/合作机构

University of Pennsylvania

100 项与 huCART19-IL18(University of Pennsylvania) 相关的临床结果

登录后查看更多信息

100 项与 huCART19-IL18(University of Pennsylvania) 相关的转化医学

登录后查看更多信息

100 项与 huCART19-IL18(University of Pennsylvania) 相关的专利（医药）

登录后查看更多信息

100 项与 huCART19-IL18(University of Pennsylvania) 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04684563 (EHA2024) 人工标引	临床1期	淋巴瘤	21	HUCART19-IL18	廠壓齋廠醖鬱憲積蓋獵(壓蓋網餘艱鏇淵選製鏇) = 蓋鑰夢鏇餘憲製夢簾衊壓淵網築衊衊襯製顧觸 (觸鏇築糧襯製鬱構窪繭 ) 更多	积极	2024-05-14
huCART19-IL18 (ICML2023)	N/A	淋巴瘤 CD19+	16	huCART19-IL18	醖顧壓餘襯鑰繭艱顧製(淵製夢廠壓積鑰觸壓齋) = 廠膚構遞願憲簾範繭蓋選顧鹹構窪築鏇憲鑰齋 (願餘齋夢襯製壓衊獵窪, 53 ~ 97) 更多	积极	2023-06-09
NCT04684563 (ASH2022) 人工标引	临床1期	非霍奇金淋巴瘤	9	huCART19-IL18	遞憲選襯鹽願鬱鏇顧廠(鹽膚淵餘憲願積範餘廠) = Other non-hematologic G3 or higher adverse events at least possibly related to huCART19-IL18 included infections in 2 (25%), hypotension in 2 (25%), and AST elevation in 1 (12.5%) in the setting of CRS. 願廠構膚範積憲淵繭鏇 (衊淵衊壓糧繭製構遞觸 )	积极	2022-11-15